Cornerstone Capital Management Holdings LLC. Raises Holdings in China Biologic Products Holdings, Inc. (CBPO)

Cornerstone Capital Management Holdings LLC. raised its stake in China Biologic Products Holdings, Inc. (NASDAQ:CBPO) by 31.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 363,190 shares of the biopharmaceutical company’s stock after purchasing an additional 85,909 shares during the period. Cornerstone Capital Management Holdings LLC. owned approximately 1.32% of China Biologic Products worth $33,511,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Jennison Associates LLC raised its stake in shares of China Biologic Products by 0.8% in the 2nd quarter. Jennison Associates LLC now owns 5,775 shares of the biopharmaceutical company’s stock valued at $653,000 after buying an additional 44 shares in the last quarter. OxFORD Asset Management LLP raised its stake in shares of China Biologic Products by 1.6% in the 2nd quarter. OxFORD Asset Management LLP now owns 14,748 shares of the biopharmaceutical company’s stock valued at $1,668,000 after buying an additional 236 shares in the last quarter. Legal & General Group Plc raised its stake in shares of China Biologic Products by 41.2% in the 3rd quarter. Legal & General Group Plc now owns 2,966 shares of the biopharmaceutical company’s stock valued at $274,000 after buying an additional 865 shares in the last quarter. California Public Employees Retirement System raised its stake in shares of China Biologic Products by 3.1% in the 2nd quarter. California Public Employees Retirement System now owns 29,500 shares of the biopharmaceutical company’s stock valued at $3,336,000 after buying an additional 900 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of China Biologic Products by 15.4% in the 1st quarter. Geode Capital Management LLC now owns 14,309 shares of the biopharmaceutical company’s stock valued at $1,432,000 after buying an additional 1,906 shares in the last quarter. 65.67% of the stock is owned by hedge funds and other institutional investors.

Separately, Zacks Investment Research upgraded shares of China Biologic Products from a “sell” rating to a “hold” rating in a research note on Wednesday, November 15th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $137.50.

China Biologic Products Holdings, Inc. (CBPO) opened at $78.43 on Friday. The stock has a market cap of $2,244.92, a price-to-earnings ratio of 18.11, a PEG ratio of 1.33 and a beta of 1.78. China Biologic Products Holdings, Inc. has a one year low of $72.21 and a one year high of $120.46.

TRADEMARK VIOLATION NOTICE: This news story was first posted by Stock Observer and is owned by of Stock Observer. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://www.thestockobserver.com/2017/12/08/cornerstone-capital-management-holdings-llc-raises-holdings-in-china-biologic-products-holdings-inc-cbpo.html.

About China Biologic Products

Want to see what other hedge funds are holding CBPO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for China Biologic Products Holdings, Inc. (NASDAQ:CBPO).

Institutional Ownership by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply